Pharmacology Department, Medical Division, National Research Centre, Giza, Egypt.
Pathology Department, Medical Division, National Research Centre, Giza, Egypt.
PLoS One. 2019 May 8;14(5):e0216301. doi: 10.1371/journal.pone.0216301. eCollection 2019.
In liver fibrosis, conversion of fibroblasts to profibrogenic myofibroblasts significantly drives the development of the disease. A crucial role of cyclic adenosine monophosphate (cAMP) in regulation of fibroblast function has been reported. Increase in cAMP levels has been found to decrease fibroblast proliferation, inhibit their conversion to myofibroblast, and stimulate their death. cAMP is generated by adenyl cyclase (AC), and degraded by cyclic nucleotide phosphodiesterase (PDE). In this study, the antifibrotic effect of a PDE inhibitor, cilostazol (Cilo), on a rat model of liver fibrosis induced by thioacetamide (TAA) was investigated. Four groups of rats were used; the first group received the vehicles and served as the normal control group, while liver fibrosis was induced in the other groups using (TAA, 200 mg/kg/biweekly for 8 successive weeks, ip). The last two groups were treated with Cilo (50 and 100 mg/kg/day, po, respectively). Induction of liver fibrosis in TAA-treated rats was observed as evidenced by the biochemical and histopathological findings. On the other hand, a potent antifibrotic effect was observed in the groups treated with Cilo, with preference to the higher dose. In these groups, a significant increase in the liver content of cAMP was demonstrated that was accompanied by reduction in the hepatic expression of key fibrogenic cytokines, growth factors, and inflammatory biomarkers, including interleukin-6, tumor necrosis factor-alpha, nuclear factor kappa B, and transforming growth factor-beta as compared to TAA group. Moreover, amelioration of TAA-induced oxidative stress and apoptosis in the liver has been observed. These findings reveal the antifibrotic effect of Cilo against TAA-induced liver fibrosis in rats, and suggest regulation of cAMP pathway, together with the modulation of oxidative stress, inflammation, and apoptosis as mechanistic cassette underlines this effect.
在肝纤维化中,成纤维细胞向促纤维化的肌成纤维细胞的转化显著促进了疾病的发展。已经报道了环腺苷酸(cAMP)在调节成纤维细胞功能中的关键作用。发现 cAMP 水平的增加可降低成纤维细胞的增殖,抑制其向肌成纤维细胞的转化,并刺激其死亡。cAMP 是由腺苷酸环化酶(AC)生成的,并被环核苷酸磷酸二酯酶(PDE)降解。在这项研究中,研究了 PDE 抑制剂西洛他唑(Cilo)对硫代乙酰胺(TAA)诱导的大鼠肝纤维化模型的抗纤维化作用。使用了四组大鼠;第一组接受载体,作为正常对照组,而其他组则使用(TAA,200mg/kg/两周,连续 8 周,ip)诱导肝纤维化。后两组分别用 Cilo(50 和 100mg/kg/天,po)治疗。TAA 处理大鼠的肝纤维化诱导如生化和组织病理学发现所证明。另一方面,在接受 Cilo 治疗的组中观察到了强大的抗纤维化作用,高剂量组的效果更好。在这些组中,肝组织中 cAMP 的含量显著增加,同时肝纤维化关键细胞因子、生长因子和炎症生物标志物(包括白细胞介素-6、肿瘤坏死因子-α、核因子 κB 和转化生长因子-β)的表达减少。此外,还观察到 TAA 诱导的肝氧化应激和细胞凋亡得到改善。这些发现揭示了 Cilo 对大鼠 TAA 诱导的肝纤维化的抗纤维化作用,并表明 cAMP 途径的调节以及氧化应激、炎症和细胞凋亡的调节是这种作用的机制基础。